Lucis secures $20M to scale AI-powered preventive healthcare in Europe
Lucis has closed a $20 million Series A round led by Singular to expand its AI-driven preventive health platform across Europe. The Paris-based startup combines deep biomarker testing, longitudinal health data, and physician-reviewed AI insights to identify risk long before symptoms appear and to guide personalized lifestyle and nutritional changes.
Revolutionizing health with data and AI
Lucis analyzes more than 110 biomarkers alongside users’ health histories to create actionable, physician-verified recommendations. The platform prioritizes early risk detection and ongoing monitoring, focusing on non-pharmacological interventions where appropriate. CEO Maxime Berthelot says the goal is to move healthcare from late-stage diagnosis to proactive prevention, using AI to scale clinical expertise without replacing medical judgment.
Demonstrating impact and rapid expansion
Early outcomes suggest clinical promise. Lucis reports that 75% of participants improved at least three biomarkers without starting medication, while 80% returned for follow-up testing. Nearly all initial assessments identified at least one actionable issue. The company serves more than 10,000 users and has processed over 1 million biomarker measures across France, the UK, Ireland, and Portugal.
With the new funding, Lucis plans to accelerate personalization, broaden physician oversight, and enter Spain, Germany, and Italy in the coming months.
Investor confidence in AI’s clinical future
Singular highlighted Lucis’s combination of clinical credibility and scalable AI as a core investment thesis. Jeremy Uzan commented that the company is well positioned to make prevention a default option in healthcare by turning biomarker signals into practical, medically vetted plans at population scale.
Lucis’s funding round and early results underscore a wider shift in European health tech toward data-driven prevention. The company aims to prove that timely detection plus personalized, physician-reviewed guidance can reduce downstream morbidity and healthcare costs while empowering individuals to manage their long-term health.
